How BIO-Europe is expanding beyond dealmaking in 2026

What It Covers

Bio Europe 2026, returning to Cologne November 9–11 for its 32nd edition, expands from three to seven content tracks, adding regulatory affairs, clinical development, and biomanufacturing programming, alongside a new content-only registration pass designed to bring the full biopharma C-suite into a conference historically dominated by business development professionals.

Key Questions Answered

• •Content track expansion: Bio Europe grows from three to seven tracks in 2026, adding regulatory affairs, clinical development, biomanufacturing, and an expanded plenary "big picture" series. Companies should audit which C-suite roles—CSO, CMO, COO—now have relevant programming and send those leaders rather than defaulting to BD-only delegations as in previous years.
• •Content-only registration pass: A new pass tier targets professionals in clinical, regulatory, and manufacturing functions who have no need for 30-minute partnering meetings but benefit from strategic discussions. Companies should evaluate this lower-barrier entry point for specialists who previously had no reason to attend, expanding their organization's presence without full partnering costs.
• •Strategic attendance timing for small biotechs: Early-stage companies should align Bio Europe attendance with specific internal milestones—fundraising rounds, partnership searches, or service procurement—rather than attending annually. The event's high retention rate combined with deliberate milestone-based attendance creates more productive meetings and stronger long-term relationship compounding across multi-year drug development timelines.
• •Biomanufacturing as a C-suite priority: Bio Europe's new manufacturing track reflects an industry shift where commercial, regulatory, and clinical strategies now intersect directly with manufacturing decisions. Companies building long-term commercial strategies should elevate biomanufacturing planning to a primary boardroom agenda item earlier in development, not treat it as a downstream operational concern.
• •Geopolitical agenda integration: The 2026 plenary series addresses MFN pricing policy, US tariffs, manufacturing reshoring pressure, and global clinical trial regulation—topics that directly affect company strategy. BD and executive teams should arrive with prepared positions on these issues, as Bio Europe positions itself as a neutral platform for generating actionable industry responses rather than simply hosting debate.